# Core C: Clinical and Biostatistic Core

> **NIH NIH U19** · EMORY UNIVERSITY · 2020 · $380,203

## Abstract

Dengue and yellow fever viruses (YFV) cause some of the most important mosquito-borne diseases with
extensive morbidity and mortality around the world. Yellow fever virus causes an acute hemorrhagic fever
complicated by hepatitis, renal failure, coagulation abnormalities, and in severe cases, death. Currently, there
are large outbreaks of yellow fever in countries in West Africa and South America. A live, attenuated yellow fever
vaccine (YFV-17D) has been in use since the 1930s and is highly efficacious in preventing yellow fever. It
provides long-term immunity for over 30 years and up to a life time. The FDA licensed yellow fever vaccine
allows us an opportunity to study the underlying immunological mechanisms that confer long term protective
immunity in humans. Dengue virus infection is the most prevalent mosquito-borne infectious disease in the world.
There are four distinct, but closely related serotypes of dengue virus (DEN-1, DEN-2, DEN-3 and DEN-4).
Recovery from infection by one serotype does not provide protective immunity to another. The incidence of
dengue fever and a more severe form of dengue known as dengue hemorrhagic fever have increased
dramatically worldwide with 40% of world’s population in over 100 countries being at risk. Understanding
protective immune responses and long-term immunity in natural infection is key for vaccine development.
Knowledge gained from these studies will inform the immune responses needed for a safe and effective dengue
vaccine. In the past and current CCHI funding cycles, the Clinical Core has been a vital component of the Emory
CCHI program and continues to support the CCHI scientific agenda for over 10 years. The Core has three units:
(1) Hope Clinic Unit at Emory University, Atlanta, GA (2) Dengue Clinical Unit at Siriraj Hospital of Mahidol
University, in Bangkok, Thailand; (3) Statistical Unit at Emory University, Atlanta, GA. In this proposal, we plan
to continue to perform novel innate and cellular immunity studies along with state-of-the art single cell and
integrated genomics to advance our fundamental understanding of immune memory, innate immunity, immune
senescence. The Hope Clinic Unit will continue studies with the YFV vaccine clinical studies to provide
appropriate specimens for Projects 1, 2 and 3. The Dengue Clinical Unit at Siriraj Hospital in Bangkok, Thailand
will continue with the dengue studies from acutely infected children and adults. The innate immunity and immune
senescence work will continue at Stanford University.

## Key facts

- **NIH application ID:** 9893786
- **Project number:** 5U19AI057266-17
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Srilatha Edupuganti
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $380,203
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9893786

## Citation

> US National Institutes of Health, RePORTER application 9893786, Core C: Clinical and Biostatistic Core (5U19AI057266-17). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9893786. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*